metoclopramide has been researched along with Critical Illness in 36 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eligible patients were those who were mechanically ventilated and over 20 years old, with delayed gastric emptying (DGE), defined as a gastric residual volume ≥250 ml or vomiting, and who failed to respond to first-line prokinetic treatment of 3 doses of 10 mg IV metoclopramide over 24 h." | 9.22 | A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastr ( Allan, K; Brown, J; Greenwood, R; Manara, A; McWilliam, H; Taylor, SJ; Toher, D, 2016) |
| "This study aimed to a) compare the efficacy of metoclopramide and erythromycin in the treatment of feed intolerance in critical illness; and b) determine the effectiveness of "rescue" combination therapy in patients who fail monotherapy." | 9.12 | Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illness. ( Bryant, LK; Chapman, MJ; Fraser, RJ; Holloway, RH; Nguyen, NQ, 2007) |
| "Eligible patients were those who were mechanically ventilated and over 20 years old, with delayed gastric emptying (DGE), defined as a gastric residual volume ≥250 ml or vomiting, and who failed to respond to first-line prokinetic treatment of 3 doses of 10 mg IV metoclopramide over 24 h." | 5.22 | A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastr ( Allan, K; Brown, J; Greenwood, R; Manara, A; McWilliam, H; Taylor, SJ; Toher, D, 2016) |
| " Adverse events (AEs) were recorded from the time of consent through to day 5; serious AEs were collected to day 30." | 3.01 | Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding Intolerance. ( Almansa, C; Barnes, CN; Chapman, MJ; Deane, AM; Jones, KL; Nguyen, D, 2021) |
| " Other secondary outcomes were comparable, and the incidence of adverse events was not significantly different between the 2 groups." | 3.01 | Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo ( Bhurayanontachai, R; Boonpeng, A; Charoensareerat, T; Lerkiatbundit, S; Navasakulpong, A; Pattharachayakul, S; Sitaruno, S, 2021) |
| "Malnourishment is prevalent in patients suffering from head and neck cancer." | 3.01 | Digestion-Specific Acupuncture Effect on Feeding Intolerance in Critically Ill Post-Operative Oral and Hypopharyngeal Cancer Patients: A Single-Blind Randomized Control Trial. ( Ben-Arie, E; Chang, CM; Chen, HC; Ho, WC; Huang, TC; Kao, PY; Lee, YC; Wei, TH, 2021) |
| "The pediatric Critical Illness Stress-induced Immune Suppression (CRISIS) trial compared the effectiveness of 2 nutraceutical supplementation strategies and found no difference in the development of nosocomial infection and sepsis in the overall population." | 2.84 | Interaction Between 2 Nutraceutical Treatments and Host Immune Status in the Pediatric Critical Illness Stress-Induced Immune Suppression Comparative Effectiveness Trial. ( Anand, KJS; Bell, MJ; Berg, RA; Berger, J; Burr, J; Carcillo, JA; Dalton, H; Dean, JM; Doctor, A; Harrison, R; Heidemann, SM; Holubkov, R; Jenkins, TL; Meert, KL; Newth, CJL; Nicholson, C; Shanley, TP; Tamburro, RF; Webster, A; Willson, DF; Zimmerman, JJ, 2017) |
| "Metoclopramide is a useful prokinetic drug in this patient population." | 2.69 | Metoclopramide improves gastric motility in critically ill patients. ( Collee, G; Jooste, CA; Mustoe, J, 1999) |
| " We have reviewed the evidence for safety, effectiveness and dosing of metoclopramide in critically ill patients." | 2.50 | Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients? ( Heyland, DK; van der Meer, YG; van Zanten, AR; Venhuizen, WA, 2014) |
| "Malnutrition is associated with poor outcomes in critically ill patients, and providing enteral feeding to those who cannot eat is considered best practice." | 2.46 | Current and future therapeutic prokinetic therapy to improve enteral feed intolerance in the ICU patient. ( Bryant, L; Fraser, RJ, 2010) |
| "The National Institutes of Health-appointed CRISIS Data and Safety Monitoring Board was charged with monitoring sample size adequacy and feasibility, safety with respect to adverse events and 28-day mortality, and efficacy with respect to the primary nosocomial infection/sepsis outcome." | 1.39 | The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study. ( Anand, KJ; Berger, J; Casper, TC; Dean, JM; Harrison, R; Holubkov, R; Meert, KL; Newth, CJ; Nicholson, C; Willson, DF; Zimmerman, J, 2013) |
| "To develop a semi-mechanistic population pharmacokinetic model based on gastric emptying function for acetaminophen plasma concentration in critically ill patients tolerant and intolerant to enteral nutrition before and after prokinetic therapy." | 1.37 | A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients. ( Aarons, L; Dukes, G; Maclaren, R; Ogungbenro, K; Vasist, L; Young, M, 2011) |
| "Metoclopramide is a dopamine receptor antagonist and, in large doses, has been shown to reverse the increase in renal blood flow, the diuresis and the natriuresis produced by a low-dose infusion of dopamine." | 1.29 | Effect of metoclopramide on renal vascular resistance index and renal function in patients receiving a low-dose infusion of dopamine. ( Bolsin, S; Hronek, I; Lowson, S; Munn, J; Tooley, M; Willcox, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (8.33) | 18.2507 |
| 2000's | 7 (19.44) | 29.6817 |
| 2010's | 20 (55.56) | 24.3611 |
| 2020's | 6 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gray, M | 1 |
| Priyanka, P | 1 |
| Kane-Gill, S | 1 |
| Wang, L | 1 |
| Kellum, JA | 1 |
| Chapman, MJ | 3 |
| Jones, KL | 1 |
| Almansa, C | 1 |
| Barnes, CN | 1 |
| Nguyen, D | 1 |
| Deane, AM | 2 |
| Charoensareerat, T | 1 |
| Bhurayanontachai, R | 1 |
| Sitaruno, S | 1 |
| Navasakulpong, A | 1 |
| Boonpeng, A | 1 |
| Lerkiatbundit, S | 1 |
| Pattharachayakul, S | 1 |
| Ben-Arie, E | 1 |
| Wei, TH | 1 |
| Chen, HC | 1 |
| Huang, TC | 1 |
| Ho, WC | 1 |
| Chang, CM | 1 |
| Kao, PY | 1 |
| Lee, YC | 1 |
| Vijayaraghavan, R | 1 |
| Maiwall, R | 1 |
| Arora, V | 1 |
| Choudhary, A | 1 |
| Benjamin, J | 1 |
| Aggarwal, P | 1 |
| Jamwal, KD | 1 |
| Kumar, G | 1 |
| Joshi, YK | 1 |
| Sarin, SK | 1 |
| Rahat-Dahmardeh, A | 1 |
| Saneie-Moghadam, S | 1 |
| Khosh-Fetrat, M | 1 |
| Taylor, SJ | 1 |
| Allan, K | 1 |
| McWilliam, H | 1 |
| Manara, A | 1 |
| Brown, J | 1 |
| Greenwood, R | 1 |
| Toher, D | 1 |
| Lv, B | 1 |
| Hu, L | 1 |
| Chen, L | 1 |
| Hu, B | 2 |
| Zhang, Y | 2 |
| Ye, H | 2 |
| Sun, C | 2 |
| Zhang, X | 1 |
| Lan, H | 1 |
| Chen, C | 2 |
| Heyland, DK | 3 |
| van Zanten, ARH | 1 |
| Grau-Carmona, T | 1 |
| Evans, D | 1 |
| Beishuizen, A | 1 |
| Schouten, J | 1 |
| Hoiting, O | 1 |
| Bordejé, ML | 1 |
| Krell, K | 1 |
| Klein, DJ | 1 |
| Gonzalez, J | 1 |
| Perez, A | 1 |
| Brown, R | 1 |
| James, J | 1 |
| Harris, MS | 1 |
| Arabi, YM | 1 |
| Reintam Blaser, A | 1 |
| Preiser, JC | 1 |
| Acosta-Escribano, J | 1 |
| Almanza López, S | 1 |
| Plumed Martín, L | 1 |
| García Martinez, MA | 1 |
| Tajadura Manjarín, N | 1 |
| van Zanten, AR | 2 |
| van der Meer, YG | 2 |
| Venhuizen, WA | 2 |
| Yip, KF | 1 |
| Rai, V | 1 |
| Wong, KK | 1 |
| Hersch, M | 1 |
| Krasilnikov, V | 1 |
| Helviz, Y | 1 |
| Zevin, S | 1 |
| Reissman, P | 1 |
| Einav, S | 1 |
| Lao, Z | 1 |
| Wu, F | 1 |
| Liu, Z | 2 |
| Huang, L | 1 |
| Qu, C | 1 |
| Xian, L | 1 |
| Wu, H | 1 |
| Jiao, Y | 1 |
| Liu, J | 1 |
| Cai, J | 1 |
| Chen, W | 1 |
| Nie, Z | 1 |
| Lewis, K | 1 |
| Alqahtani, Z | 1 |
| Mcintyre, L | 1 |
| Almenawer, S | 1 |
| Alshamsi, F | 1 |
| Rhodes, A | 1 |
| Evans, L | 1 |
| Angus, DC | 1 |
| Alhazzani, W | 1 |
| Carcillo, JA | 2 |
| Dean, JM | 3 |
| Holubkov, R | 3 |
| Berger, J | 3 |
| Meert, KL | 3 |
| Anand, KJS | 1 |
| Zimmerman, JJ | 1 |
| Newth, CJL | 1 |
| Harrison, R | 3 |
| Burr, J | 2 |
| Willson, DF | 3 |
| Nicholson, C | 3 |
| Bell, MJ | 1 |
| Berg, RA | 1 |
| Shanley, TP | 1 |
| Heidemann, SM | 1 |
| Dalton, H | 1 |
| Jenkins, TL | 1 |
| Doctor, A | 1 |
| Webster, A | 1 |
| Tamburro, RF | 1 |
| Malekolkottab, M | 1 |
| Khalili, H | 1 |
| Mohammadi, M | 1 |
| Ramezani, M | 1 |
| Nourian, A | 1 |
| Baradari, AG | 1 |
| Khajavi, MR | 1 |
| Firouzian, A | 1 |
| Alipour, A | 1 |
| Daneshpour, H | 1 |
| Panahi, Y | 1 |
| Sahebkar, A | 1 |
| Fraser, RJ | 4 |
| Lu, NF | 1 |
| Zheng, RQ | 1 |
| Lin, H | 1 |
| Yang, DG | 1 |
| Chen, QH | 1 |
| Shao, J | 1 |
| Yu, JQ | 1 |
| Bryant, L | 1 |
| Ogungbenro, K | 1 |
| Vasist, L | 1 |
| Maclaren, R | 3 |
| Dukes, G | 1 |
| Young, M | 1 |
| Aarons, L | 1 |
| Ridley, EJ | 1 |
| Davies, AR | 1 |
| Anand, KJ | 2 |
| Zimmerman, J | 2 |
| Newth, CJ | 2 |
| Casper, TC | 1 |
| Nguyen, NQ | 2 |
| Bryant, LK | 2 |
| Holloway, RH | 2 |
| Asai, T | 1 |
| Chapman, M | 1 |
| Burgstad, C | 1 |
| Heiselman, DE | 1 |
| Hofer, T | 1 |
| Vidovich, RR | 1 |
| Munn, J | 1 |
| Tooley, M | 1 |
| Bolsin, S | 1 |
| Hronek, I | 1 |
| Lowson, S | 1 |
| Willcox, J | 1 |
| Jooste, CA | 1 |
| Mustoe, J | 1 |
| Collee, G | 1 |
| Kuhl, DA | 1 |
| Gervasio, JM | 1 |
| Brown, RO | 1 |
| Dickerson, RN | 1 |
| Livingston, TN | 1 |
| Swift, K | 1 |
| Headley, S | 1 |
| Kudsk, KA | 1 |
| Lima, JJ | 2 |
| Schuster-Bruce, M | 1 |
| Patrick, WD | 1 |
| Hall, RI | 1 |
| Rocker, GM | 1 |
| Whelan, GJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance[NCT01953081] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Randomized Controlled Trial of Metoclopramide Versus Placebo During Gastrojejunostomy Tube Placement for Facilitating Guidewire Advancement Through the Pylorus[NCT03331965] | Phase 2 | 110 participants (Actual) | Interventional | 2018-04-09 | Completed | ||
| The Critical Illness Stress-induced Immune Suppression Prevention Trial[NCT00395161] | Phase 3 | 293 participants (Actual) | Interventional | 2007-04-30 | Terminated (stopped due to Terminated for futility on 11/30/09 based on the recommendation of the DSMB) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
the number of subjects reporting adverse events by treatment group (NCT01953081)
Timeframe: 6 Days
| Intervention | participants (Number) |
|---|---|
| TD-8954 | 5 |
| Metoclopramide | 4 |
Area under the plasma concentration time curve from 0 to 72 hours after dosing. (NCT01953081)
Timeframe: 72 hours
| Intervention | pg*hr/mL (Mean) |
|---|---|
| TD-8954 | 23200 |
Maximum plasma concentration (NCT01953081)
Timeframe: 72 hours
| Intervention | pg/mL (Mean) |
|---|---|
| TD-8954 | 5040 |
Time to 1/2 gastric emptying by breath test (NCT01953081)
Timeframe: 180 minutes
| Intervention | minutes (Mean) |
|---|---|
| TD-8954 | 135.7 |
| Metoclopramide | 132.5 |
Number of subjects with retention less than 13% at 180 minutes after dosing. (NCT01953081)
Timeframe: 180 minutes
| Intervention | participants (Number) |
|---|---|
| TD-8954 | 6 |
| Metoclopramide | 3 |
Mean gastric retention percentage after dosing. (NCT01953081)
Timeframe: 120 minutes
| Intervention | percentage of retention (Mean) |
|---|---|
| TD-8954 | 19.6 |
| Metoclopramide | 32.3 |
Mean gastric retention percentage after dosing. (NCT01953081)
Timeframe: 60 minutes
| Intervention | percentage of retention (Mean) |
|---|---|
| TD-8954 | 29.6 |
| Metoclopramide | 43.3 |
Mean gastric retention percentage after dosing. (NCT01953081)
Timeframe: 240 minutes
| Intervention | percentage of retention (Mean) |
|---|---|
| TD-8954 | 11.1 |
| Metoclopramide | 16.3 |
Time to maximal concentration in plasma (NCT01953081)
Timeframe: 72 hours
| Intervention | hours (Median) |
|---|---|
| TD-8954 | 0.500 |
To assess the safety of a single dose of promotility agent prior to GJ tube placement by assessing rates of adverse events in the periprocedural period in patients receiving IV metoclopramide versus placebo. (NCT03331965)
Timeframe: Up to 30 days after procedure.
| Intervention | Participants (Count of Participants) |
|---|---|
| Metoclopramide | 0 |
| Saline | 0 |
The fluoroscopy time required to advance a guidewire through the pylorus. (NCT03331965)
Timeframe: Up to 45 minutes.
| Intervention | Minutes (Mean) |
|---|---|
| Metoclopramide | 1.6 |
| Saline | 4.1 |
The total procedure Air Kerma (energy released in a unit mass of air) measured in milligray (mGy). (NCT03331965)
Timeframe: Up to 1 hour.
| Intervention | mGy (Mean) |
|---|---|
| Metoclopramide | 91 |
| Saline | 130 |
The total procedure fluoroscopy time. (NCT03331965)
Timeframe: Up to 1 hour.
| Intervention | Minutes (Mean) |
|---|---|
| Metoclopramide | 5.8 |
| Saline | 8.8 |
The total procedure time. (NCT03331965)
Timeframe: Up to 1 hour.
| Intervention | Minutes (Mean) |
|---|---|
| Metoclopramide | 16.4 |
| Saline | 19.9 |
(NCT00395161)
Timeframe: 28 days after admission to the PICU
| Intervention | participants (Number) |
|---|---|
| Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide | 15 |
| Enteral Whey Protein, IV Saline | 8 |
(NCT00395161)
Timeframe: 48 hours after admission until PICU discharge
| Intervention | Days (Median) |
|---|---|
| Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide | 1 |
| Enteral Whey Protein, IV Saline | 2 |
What is reported is the number of participants with counts qualifying as lymphopenia. (NCT00395161)
Timeframe: from time of PICU admission till discharge from PICU
| Intervention | participants (Number) |
|---|---|
| Enteral Zinc, Selenium, Glutamine, and IV Metoclopramide | 5 |
| Enteral Whey Protein, IV Saline | 12 |
(NCT00395161)
Timeframe: 48 hours after PICU admission till discharge from PICU
| Intervention | Mean number of events per 100 study days (Mean) |
|---|---|
| Daily Nutriceutical Supplementation | 4.99 |
| Whey Protein | 4.83 |
(NCT00395161)
Timeframe: 48 hours after admission until 5 days after discharged from the PICU
| Intervention | Days (Median) |
|---|---|
| Daily Nutriceutical Supplementation | 12.1 |
| Whey Protein | 13.2 |
5 reviews available for metoclopramide and Critical Illness
| Article | Year |
|---|---|
Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients?
Topics: Critical Illness; Dose-Response Relationship, Drug; Drug Prescriptions; Humans; Metoclopramide; Nerv | 2014 |
The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials.
Topics: Chi-Square Distribution; Critical Illness; Diarrhea; Domperidone; Dopamine Antagonists; Enteral Nutr | 2016 |
Prokinetic drugs for feed intolerance in critical illness: current and potential therapies.
Topics: Antiemetics; Cholecystokinin; Critical Illness; Dopamine Antagonists; Drug Therapy, Combination; Ent | 2009 |
Current and future therapeutic prokinetic therapy to improve enteral feed intolerance in the ICU patient.
Topics: Critical Illness; Enteral Nutrition; Erythromycin; Gastric Emptying; Gastrointestinal Agents; Gastro | 2010 |
Practicalities of nutrition support in the intensive care unit: the usefulness of gastric residual volume and prokinetic agents with enteral nutrition.
Topics: Critical Illness; Enteral Nutrition; Erythromycin; Gastric Emptying; Gastric Mucosa; Gastrointestina | 2011 |
22 trials available for metoclopramide and Critical Illness
| Article | Year |
|---|---|
Blinded, Double-Dummy, Parallel-Group, Phase 2a Randomized Clinical Trial to Evaluate the Efficacy and Safety of a Highly Selective 5-Hydroxytryptamine Type 4 Receptor Agonist in Critically Ill Patients With Enteral Feeding Intolerance.
Topics: Critical Illness; Double-Blind Method; Enteral Nutrition; Gastric Emptying; Humans; Infant, Newborn; | 2021 |
Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo
Topics: Critical Illness; Enteral Nutrition; Erythromycin Estolate; Gastric Emptying; Humans; Infant, Newbor | 2021 |
Digestion-Specific Acupuncture Effect on Feeding Intolerance in Critically Ill Post-Operative Oral and Hypopharyngeal Cancer Patients: A Single-Blind Randomized Control Trial.
Topics: Acupuncture Therapy; Aged; China; Critical Illness; Digestion; Energy Intake; Energy Metabolism; Hum | 2021 |
Reversal of Feed Intolerance by Prokinetics Improves Survival in Critically Ill Cirrhosis Patients.
Topics: Critical Illness; Enteral Nutrition; Erythromycin; Humans; Intensive Care Units; Liver Cirrhosis; Me | 2022 |
Comparing the Effect of Neostigmine and Metoclopramide on Gastric Residual Volume of Mechanically Ventilated Patients in Intensive Care Unit: A Double-Blind Randomized Clinical Trial.
Topics: Antiemetics; Critical Illness; Double-Blind Method; Female; Gastric Emptying; Humans; Intensive Care | 2021 |
A randomised controlled feasibility and proof-of-concept trial in delayed gastric emptying when metoclopramide fails: We should revisit nasointestinal feeding versus dual prokinetic treatment: Achieving goal nutrition in critical illness and delayed gastr
Topics: Adult; Critical Illness; Enteral Nutrition; Erythromycin; Female; Gastric Emptying; Gastrointestinal | 2016 |
Blind bedside postpyloric placement of spiral tube as rescue therapy in critically ill patients: a prospective, tricentric, observational study.
Topics: Aged; Antiemetics; Critical Illness; Enteral Nutrition; Female; Humans; Intensive Care Units; Intuba | 2017 |
A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial.
Topics: Adult; Aged; Antiemetics; APACHE; Canada; Critical Illness; Double-Blind Method; Enteral Nutrition; | 2019 |
[The metoclopramide effect on enteral nutrition tolerance and mechanical ventilation associated pneumonia in neuro critically ill patients].
Topics: Adult; Aged; Antiemetics; Critical Illness; Enteral Nutrition; Female; Gastrointestinal Diseases; Hu | 2014 |
Prokinetic drugs for gastric emptying in critically ill ventilated patients: Analysis through breath testing.
Topics: Adult; Aged; Aged, 80 and over; Breath Tests; Carbon Isotopes; Critical Care; Critical Illness; Cros | 2015 |
Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; APACHE; Critical Illness; Domperidone; Ente | 2015 |
Interaction Between 2 Nutraceutical Treatments and Host Immune Status in the Pediatric Critical Illness Stress-Induced Immune Suppression Comparative Effectiveness Trial.
Topics: Adolescent; Child; Child, Preschool; Critical Illness; Cross Infection; Dietary Supplements; Female; | 2017 |
Metoclopramide as intermittent and continuous infusions in critically ill patients: a pilot randomized clinical trial.
Topics: Adult; Aged; Antiemetics; Critical Illness; Drug Administration Schedule; Energy Intake; Enteral Nut | 2017 |
Effects of combined prokinetic administration on gastric emptying in critically ill patients.
Topics: Adult; Critical Illness; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Double- | 2017 |
[Study of erythromycin and metoclopramide in treatment of feeding intolerance of critically ill patients in intensive care unit].
Topics: Aged; Critical Illness; Enteral Nutrition; Erythromycin; Female; Gastric Emptying; Gastrointestinal | 2010 |
The randomized comparative pediatric critical illness stress-induced immune suppression (CRISIS) prevention trial.
Topics: Adolescent; Child; Child, Preschool; Critical Illness; Cross Infection; Dietary Supplements; Double- | 2012 |
Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illness.
Topics: Critical Illness; Dopamine Antagonists; Double-Blind Method; Enteral Nutrition; Erythromycin; Female | 2007 |
Prokinetic therapy for feed intolerance in critical illness: one drug or two?
Topics: Antiemetics; Critical Illness; Double-Blind Method; Drug Therapy, Combination; Enteral Nutrition; Er | 2007 |
Enteral feeding tube placement success with intravenous metoclopramide administration in ICU patients.
Topics: Critical Illness; Enteral Nutrition; Humans; Injections, Intravenous; Intensive Care Units; Intubati | 1995 |
Metoclopramide improves gastric motility in critically ill patients.
Topics: Adult; Critical Illness; Dopamine Antagonists; Enteral Nutrition; Gastric Emptying; Humans; Intensiv | 1999 |
Sequential single doses of cisapride, erythromycin, and metoclopramide in critically ill patients intolerant to enteral nutrition: a randomized, placebo-controlled, crossover study.
Topics: Acetaminophen; Administration, Oral; Adult; Aged; Antiemetics; Cisapride; Critical Illness; Cross-Ov | 2000 |
Comparison of cisapride and metoclopramide for facilitating gastric emptying and improving tolerance to intragastric enteral nutrition in critically III, mechanically ventilated adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cisapride; Critical Illness; Dopamine Antagonists; Doubl | 2001 |
9 other studies available for metoclopramide and Critical Illness
| Article | Year |
|---|---|
Kidney and Mortality Outcomes Associated with Ondansetron in Critically Ill Patients.
Topics: Acute Kidney Injury; Antiemetics; Critical Illness; Humans; Intensive Care Units; Kidney; Metoclopra | 2022 |
When and how to manage enteral feeding intolerance?
Topics: Critical Illness; Double-Blind Method; Enteral Nutrition; Humans; Macrocyclic Compounds; Metoclopram | 2019 |
Still a Place for Metoclopramide as a Prokinetic Drug in Critically Ill Patients?
Topics: Critical Illness; Dose-Response Relationship, Drug; Enteral Nutrition; Humans; Intensive Care Units; | 2015 |
Evaluation of delivery of enteral nutrition in mechanically ventilated Malaysian ICU patients.
Topics: Adult; Aged; Critical Illness; Cross-Sectional Studies; Energy Intake; Enteral Nutrition; Female; Hu | 2014 |
A semi-mechanistic gastric emptying model for the population pharmacokinetic analysis of orally administered acetaminophen in critically ill patients.
Topics: Acetaminophen; Administration, Oral; Algorithms; Analgesics, Non-Narcotic; Antiemetics; Critical Ill | 2011 |
The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
Topics: Adolescent; Biomedical Research; Child; Child, Preschool; Clinical Trials Data Monitoring Committees | 2013 |
How should we use prokinetic drugs in patients who are intolerant to enteral feeding?
Topics: Critical Illness; Dopamine Antagonists; Enteral Nutrition; Erythromycin; Gastrointestinal Agents; Hu | 2007 |
Effect of metoclopramide on renal vascular resistance index and renal function in patients receiving a low-dose infusion of dopamine.
Topics: Adult; Critical Illness; Dopamine; Humans; Kidney; Kidney Function Tests; Metoclopramide; Vascular R | 1993 |
Gastric emptying in the critically ill.
Topics: Cisapride; Critical Illness; Dopamine Antagonists; Erythromycin; Gastric Emptying; Gastrointestinal | 2001 |